Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.
Crystal Shereen Denlinger
Research Funding - Merrimack Pharmaceuticals
Sun Jin Sym
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Maria Alsina
No relevant relationships to disclose
David Watkins
No relevant relationships to disclose
Yee Chao
No relevant relationships to disclose
Antonio Cubillo
No relevant relationships to disclose
Pamela L. Kunz
No relevant relationships to disclose
Weijing Sun
No relevant relationships to disclose
Lene Baeksgaard
No relevant relationships to disclose
Li-Tzong Chen
No relevant relationships to disclose
Kerry Horgan
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Sasha Frye
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Arthur J. Kudla
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Charlotte Fenton McDonagh
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Akos Gabor Czibere
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Victor M. Moyo
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Benoist Chibaudel
Consultant or Advisory Role - Merrimack Pharmaceuticals (U)
Yung-Jue Bang
Research Funding - Merrimack Pharmaceuticals